
BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Equities researchers at Leerink Partnrs decreased their Q3 2025 earnings per share (EPS) estimates for shares of BridgeBio Pharma in a report released on Wednesday, August 6th. Leerink Partnrs analyst M. Foroohar now expects that the company will earn ($0.83) per share for the quarter, down from their prior estimate of ($0.71). The consensus estimate for BridgeBio Pharma's current full-year earnings is ($3.67) per share. Leerink Partnrs also issued estimates for BridgeBio Pharma's Q4 2025 earnings at ($0.83) EPS, FY2025 earnings at ($3.50) EPS, FY2026 earnings at ($1.03) EPS, FY2027 earnings at $1.94 EPS and FY2028 earnings at $5.70 EPS.
Several other research firms have also issued reports on BBIO. Raymond James Financial started coverage on BridgeBio Pharma in a research note on Wednesday, July 30th. They issued an "outperform" rating and a $56.00 price objective on the stock. Oppenheimer boosted their target price on BridgeBio Pharma from $60.00 to $61.00 and gave the stock an "outperform" rating in a report on Wednesday. Citigroup raised their price target on BridgeBio Pharma from $58.00 to $67.00 and gave the company a "buy" rating in a report on Friday, July 11th. UBS Group lifted their price objective on shares of BridgeBio Pharma from $65.00 to $72.00 and gave the stock a "buy" rating in a research report on Wednesday, April 30th. Finally, Jefferies Financial Group assumed coverage on shares of BridgeBio Pharma in a research report on Monday, July 14th. They set a "buy" rating and a $70.00 price objective for the company. One investment analyst has rated the stock with a hold rating and seventeen have given a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $61.35.
Read Our Latest Stock Report on BridgeBio Pharma
BridgeBio Pharma Stock Up 1.4%
Shares of NASDAQ BBIO traded up $0.63 during trading hours on Friday, hitting $46.58. The company had a trading volume of 2,498,017 shares, compared to its average volume of 2,964,618. The stock has a market capitalization of $8.90 billion, a P/E ratio of -11.39 and a beta of 1.23. BridgeBio Pharma has a 1-year low of $21.72 and a 1-year high of $49.77. The firm's 50 day moving average is $43.66 and its 200-day moving average is $37.48.
BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.12). The firm had revenue of $110.57 million for the quarter, compared to the consensus estimate of $98.46 million. The firm's quarterly revenue was up 4999.9% on a year-over-year basis. During the same period in the prior year, the company earned ($0.39) earnings per share.
Institutional Trading of BridgeBio Pharma
Large investors have recently modified their holdings of the stock. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of BridgeBio Pharma during the 2nd quarter worth $25,000. GAMMA Investing LLC grew its holdings in shares of BridgeBio Pharma by 71.0% during the 1st quarter. GAMMA Investing LLC now owns 920 shares of the company's stock worth $32,000 after purchasing an additional 382 shares in the last quarter. Jones Financial Companies Lllp acquired a new stake in shares of BridgeBio Pharma during the 1st quarter worth $35,000. Itau Unibanco Holding S.A. acquired a new stake in shares of BridgeBio Pharma during the 4th quarter worth $41,000. Finally, Sterling Capital Management LLC grew its holdings in shares of BridgeBio Pharma by 554.6% during the 4th quarter. Sterling Capital Management LLC now owns 1,787 shares of the company's stock worth $49,000 after purchasing an additional 1,514 shares in the last quarter. 99.85% of the stock is owned by institutional investors and hedge funds.
Insider Activity
In other BridgeBio Pharma news, Director Frank Mccormick sold 100,000 shares of the stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $44.23, for a total transaction of $4,423,000.00. Following the transaction, the director owned 879,979 shares in the company, valued at $38,921,471.17. This represents a 10.20% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Andrea Ellis sold 17,167 shares of the stock in a transaction that occurred on Tuesday, August 5th. The stock was sold at an average price of $49.00, for a total transaction of $841,183.00. Following the transaction, the director owned 18,589 shares in the company, valued at approximately $910,861. The trade was a 48.01% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 9,767,322 shares of company stock worth $369,921,586. Insiders own 18.20% of the company's stock.
About BridgeBio Pharma
(
Get Free Report)
BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
Recommended Stories

Before you consider BridgeBio Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BridgeBio Pharma wasn't on the list.
While BridgeBio Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.